Tyr397
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr397  -  FAK (rat)

Site Information
SVSETDDyAEIIDEE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447887

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 9 ) , mass spectrometry ( 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 ) , microscopy-colocalization with upstream kinase ( 84 , 85 ) , mutation of modification site ( 3 , 8 , 9 , 92 , 95 , 108 , 113 , 116 , 121 ) , phospho-antibody ( 3 , 4 , 5 , 6 , 9 , 10 , 11 , 12 , 53 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 ) , western blotting ( 3 , 4 , 5 , 6 , 9 , 10 , 11 , 12 , 53 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 98 , 99 , 101 , 102 , 103 , 105 , 106 , 108 , 109 , 112 , 113 , 114 , 116 , 117 , 119 , 120 , 121 )
Disease tissue studied:
bone cancer ( 102 ) , breast cancer ( 90 , 98 ) , colorectal cancer ( 88 ) , colorectal carcinoma ( 88 ) , fibrosarcoma of soft tissue ( 8 )
Relevant cell line - cell type - tissue:
'brain, cerebral cortex' ( 115 ) , 'brain, hippocampus' ( 118 ) , 'brain, hippocampus, dentate gyrus' ( 113 ) , 'muscle, smooth' ( 11 , 119 ) , 'muscle, smooth'-'heart, artery' ( 12 ) , 'muscle, smooth'-thoracic aorta ( 107 ) , 3Y1 (fibroblast) ( 53 ) , A431 (epithelial) [FAK (human)] ( 87 ) , adipocyte ( 120 ) , beta-pancreas ( 10 ) , brain ( 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 ) , chondrocyte ( 3 ) , COS (fibroblast) ( 109 , 116 , 121 ) , COS7 (fibroblast) ( 5 ) , FG (pancreatic) ( 87 ) , fibroblast-heart ( 94 ) , hepatocyte-liver ( 9 ) , HT1080 (fibroblast) ( 8 ) , IEC-18 (epithelial) ( 88 , 101 ) , L3.6p1 (pancreatic) ( 87 ) , L6 (myoblast) ( 93 ) , lens ( 89 ) , liver ( 103 ) , MC3T3-E1 (preosteoblast) ( 102 ) , MDCK (epithelial) ( 87 ) , MTLn3 (breast cell) ( 90 , 98 ) , myocardium ( 100 ) , myocyte-heart ( 85 , 91 , 92 , 96 , 97 , 99 , 105 , 108 , 111 ) , osteoblast-calvarium ( 102 ) , pancreas ( 112 ) , PC3 (prostate cell) ( 87 ) , Rat1 (fibroblast) ( 110 ) , REF52 (fibroblast) ( 87 , 109 ) , RIE (epithelial) ( 84 , 86 ) , RM-4 (mesothelial) ( 104 ) , ROS 17/2.8 (bone cell) ( 102 ) , RPE-J (epithelial) ( 106 ) , sertoli-testis ( 114 ) , SKOV-3 (ovarian) ( 87 ) , T84 (intestinal) ( 88 ) , vascular ( 117 ) , VSMC ('muscle, smooth') ( 6 )

Upstream Regulation
Regulatory protein:
Bcl-2 (rat) ( 90 ) , FAK (human) ( 98 ) , FAK (rat) ( 12 , 85 ) , FAK iso2 (mouse) ( 119 ) , HRas (human) ( 53 ) , ILK (human) ( 84 ) , ITGA5 (human) ( 86 ) , ITGB1 (human) ( 96 ) , LIMK1 (rat) ( 84 ) , PKCD (rat) ( 86 ) , RAC1 (rat) ( 9 ) , SHP-2 (rat) ( 83 ) , TESK1 (rat) ( 84 ) , TESK2 (rat) ( 84 )
Putative in vivo kinases:
FAK (rat) ( 5 , 87 , 116 ) , Src (human) ( 121 )
Kinases, in vitro:
FAK (rat) ( 116 , 121 )
Putative upstream phosphatases:
SHP-2 (rat) ( 92 )
Phosphatases, in vitro:
PTPRZ1 (human) ( 121 )
Treatments:
2-AG ( 118 ) , 8-Rp-cAMP ( 94 ) , acadesine ( 6 ) , adriamycin ( 90 ) , AF-2364 ( 114 ) , anandamide ( 118 ) , angiopoietin-1 ( 99 ) , angiopoietin-2 ( 99 ) , angiotensin ( 107 , 108 ) , angiotensin_2 ( 12 , 88 ) , anti-ITGAv ( 106 ) , apocynin ( 9 ) , APV ( 113 ) , BAPTA-AM ( 105 ) , BDM ( 105 ) , blood pressure ( 100 , 117 ) , Ca(2+) ( 4 ) , cAMP_analog ( 94 , 118 ) , cathepsin_G ( 92 ) , CCK-JMV ( 112 ) , cell_adhesion ( 84 , 110 ) , cell_detachment ( 95 ) , chelerythrine ( 105 ) , cholecystokinin ( 112 ) , colforsin ( 94 ) , cyclic_stretch ( 83 , 85 , 97 , 108 ) , cytochalasin_D ( 86 , 97 , 105 ) , depolarization ( 4 ) , DPI ( 9 ) , DuP_753 ( 108 ) , EGF ( 9 , 88 ) , electrical_stimulation ( 113 ) , endothelin ( 105 ) , exoenzyme_C3 ( 97 ) , FGF2 ( 89 ) , fibronectin ( 53 , 84 , 86 , 109 ) , GF109203X ( 112 ) , glucose ( 10 ) , GRGDSP ( 103 ) , H-89 ( 118 ) , insulin ( 103 ) , interstitial flow ( 11 ) , ionomycin ( 4 ) , isoproterenol ( 96 ) , laminin-1 ( 99 ) , long-term_potentiation ( 113 ) , LPA ( 88 ) , LY294002 ( 84 ) , MCPG ( 113 ) , mechanical stress ( 102 ) , ML-7 ( 105 ) , ML-9 ( 4 ) , MMP-2 ( 96 ) , mutation ( 3 ) , neuregulin ( 91 ) , nifedipine ( 4 , 105 ) , NVP-TAE226 ( 4 ) , osmotic_stress ( 101 ) , OXO ( 86 ) , p18_peptide ( 84 ) , PD98059 ( 10 ) , PDGF ( 6 , 107 , 119 ) , PF-431396 ( 4 ) , PF-573228 ( 4 , 87 ) , phagocytic challenge ( 106 ) , phorbol_ester ( 88 ) , PP1 ( 117 ) , PP2 ( 83 , 84 , 102 , 103 , 105 , 108 , 116 , 118 ) , PP3 ( 105 ) , pressure ( 3 ) , PTP1B_inhibitor_compound_II ( 94 ) , Rp-cAMPS ( 118 ) , SB3CT ( 96 ) , sc-203950 ( 4 ) , siRNA ( 84 ) , SR7037 ( 10 ) , TFMS ( 83 ) , thapsigargin ( 112 ) , TIMP2 ( 96 ) , U0126 ( 9 , 84 ) , vitronectin ( 99 ) , Y15 ( 10 ) , Y27632 ( 84 , 97 , 105 ) , Z-VAD-FMK ( 90 )

Downstream Regulation
Effects of modification on FAK:
activity, induced ( 97 , 104 ) , enzymatic activity, induced ( 108 ) , intracellular localization ( 10 , 92 , 108 , 111 ) , molecular association, regulation ( 113 , 120 ) , phosphorylation ( 95 , 113 , 121 )
Effects of modification on biological processes:
apoptosis, altered ( 95 ) , apoptosis, inhibited ( 92 ) , cell adhesion, altered ( 95 ) , cytoskeletal reorganization ( 9 , 92 ) , signaling pathway regulation ( 9 ) , transcription, altered ( 95 , 108 )
Induce interaction with:
LYN (human) ( 120 ) , NMDAR2A (rat) ( 113 ) , NMDAR2B (rat) ( 113 )

References 

1

Zhang L, Zhao X, Wang W (2021) Disruption of anchoring junctions in the testes of experimental varicocele rats. Exp Ther Med 22, 887
34194565   Curated Info

2

Zhou Q, et al. (2021) Inflammatory Immune Cytokine TNF-α Modulates Ezrin Protein Activation FAK/RhoA Signaling Pathway in PMVECs Hyperpermeability. Front Pharmacol 12, 676817
34054551   Curated Info

3

Ren K, et al. (2018) Periodic Mechanical Stress Stimulates GIT1-Dependent Mitogenic Signals in Rat Chondrocytes Through ERK1/2 Activity. Cell Physiol Biochem 50, 1015-1028
30355914   Curated Info

4

Mills RD, et al. (2015) A Role for the Tyrosine Kinase Pyk2 in Depolarization-induced Contraction of Vascular Smooth Muscle. J Biol Chem 290, 8677-92
25713079   Curated Info

5

Kadaré G, et al. (2015) Conformational dynamics of the focal adhesion targeting domain control specific functions of focal adhesion kinase in cells. J Biol Chem 290, 478-91
25391654   Curated Info

6

Stone JD, et al. (2013) AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injury. Am J Physiol Heart Circ Physiol 304, H369-81
23203966   Curated Info

7

Jun HJ, et al. (2012) The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res 72, 3764-74
22659450   Curated Info

8

Wang Y, McNiven MA (2012) Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. J Cell Biol 196, 375-85
22291036   Curated Info

9

Flinder LI, et al. (2011) EGF-induced ERK-activation downstream of FAK requires rac1-NADPH oxidase. J Cell Physiol 226, 2267-78
21660950   Curated Info

10

Rondas D, Tomas A, Halban PA (2011) Focal adhesion remodeling is crucial for glucose-stimulated insulin secretion and involves activation of focal adhesion kinase and paxillin. Diabetes 60, 1146-57
21357465   Curated Info

11

Shi ZD, Wang H, Tarbell JM (2011) Heparan sulfate proteoglycans mediate interstitial flow mechanotransduction regulating MMP-13 expression and cell motility via FAK-ERK in 3D collagen. PLoS One 6, e15956
21246051   Curated Info

12

Koshman YE, et al. (2010) FRNK inhibition of focal adhesion kinase-dependent signaling and migration in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 30, 2226-33
20705914   Curated Info

13

Hu Y (2009) CST Curation Set: 8469; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

Hu Y (2009) CST Curation Set: 8472; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

15

Hu Y (2009) CST Curation Set: 8470; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

16

Hu Y (2009) CST Curation Set: 8467; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

17

Hu Y (2009) CST Curation Set: 8468; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

18

Hu Y (2009) CST Curation Set: 8463; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

19

Hu Y (2009) CST Curation Set: 8460; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

20

Hu Y (2009) CST Curation Set: 8461; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

21

Hu Y (2009) CST Curation Set: 8464; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

22

Hu Y (2009) CST Curation Set: 8448; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

23

Hu Y (2009) CST Curation Set: 8456; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

24

Hu Y (2009) CST Curation Set: 8447; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

25

Hu Y (2009) CST Curation Set: 8430; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

26

Hu Y (2009) CST Curation Set: 8429; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

27

Hu Y (2009) CST Curation Set: 8344; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

28

Hu Y (2009) CST Curation Set: 8342; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

29

Hu Y (2009) CST Curation Set: 8343; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

30

Hu Y (2009) CST Curation Set: 8341; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

31

Hu Y (2009) CST Curation Set: 8340; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

32

Hu Y (2009) CST Curation Set: 8329; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

33

Hu Y (2009) CST Curation Set: 8333; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

34

Hu Y (2009) CST Curation Set: 8332; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

35

Hu Y (2009) CST Curation Set: 8330; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

36

Hu Y (2009) CST Curation Set: 8334; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

37

Hu Y (2009) CST Curation Set: 8316; Year: 2009; Biosample/Treatment: tissue, brain/ischemia; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

38

Hu Y (2009) CST Curation Set: 8318; Year: 2009; Biosample/Treatment: tissue, brain/ischemia; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

39

Hu Y (2009) CST Curation Set: 8317; Year: 2009; Biosample/Treatment: tissue, brain/ischemia; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

40

Hu Y (2009) CST Curation Set: 8312; Year: 2009; Biosample/Treatment: tissue, brain/ischemia; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

41

Hu Y (2009) CST Curation Set: 8311; Year: 2009; Biosample/Treatment: tissue, brain/ischemia; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

42

Hu Y (2009) CST Curation Set: 8314; Year: 2009; Biosample/Treatment: tissue, brain/ischemia; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

43

Hu Y (2009) CST Curation Set: 8313; Year: 2009; Biosample/Treatment: tissue, brain/ischemia; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

44

Hu Y (2009) CST Curation Set: 8306; Year: 2009; Biosample/Treatment: tissue, brain/ischemia; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

45

Hu Y (2009) CST Curation Set: 8302; Year: 2009; Biosample/Treatment: tissue, brain/ischemia; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

46

Hu Y (2009) CST Curation Set: 8303; Year: 2009; Biosample/Treatment: tissue, brain/ischemia; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

47

Hu Y (2009) CST Curation Set: 8301; Year: 2009; Biosample/Treatment: tissue, brain/ischemia; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

48

Hu Y (2009) CST Curation Set: 8307; Year: 2009; Biosample/Treatment: tissue, brain/ischemia; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

49

Hu Y (2009) CST Curation Set: 8285; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

50

Hu Y (2009) CST Curation Set: 8284; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

51

Hu Y (2009) CST Curation Set: 8280; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

52

Hu Y (2009) CST Curation Set: 8282; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

53

Zheng Y, Lu Z (2009) Paradoxical roles of FAK in tumor cell migration and metastasis. Cell Cycle 8, 3474-9
19829089   Curated Info

54

Hu Y (2009) CST Curation Set: 8271; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

55

Hu Y (2009) CST Curation Set: 8261; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

56

Hu Y (2009) CST Curation Set: 8256; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

57

Hu Y (2009) CST Curation Set: 8253; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

58

Tucker M (2009) CST Curation Set: 7256; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

59

Tucker M (2009) CST Curation Set: 7255; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

60

Tucker M (2009) CST Curation Set: 7254; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

61

Tucker M (2009) CST Curation Set: 7257; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

62

Tucker M (2009) CST Curation Set: 7252; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

63

Tucker M (2009) CST Curation Set: 7249; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

64

Tucker M (2009) CST Curation Set: 7240; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

65

Tucker M (2009) CST Curation Set: 7239; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

66

Tucker M (2009) CST Curation Set: 7245; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

67

Tucker M (2009) CST Curation Set: 7244; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

68

Tucker M (2009) CST Curation Set: 7247; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

69

Tucker M (2009) CST Curation Set: 7242; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

70

Tucker M (2009) CST Curation Set: 7243; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

71

Tucker M (2009) CST Curation Set: 7246; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

72

Tucker M (2009) CST Curation Set: 7237; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

73

Tucker M (2009) CST Curation Set: 7236; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

74

Tucker M (2009) CST Curation Set: 7162; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

75

Tucker M (2009) CST Curation Set: 7163; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

76

Tucker M (2009) CST Curation Set: 7151; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

77

Tucker M (2009) CST Curation Set: 7150; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

78

Tucker M (2009) CST Curation Set: 7141; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

79

Tucker M (2009) CST Curation Set: 7145; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

80

Tucker M (2009) CST Curation Set: 7142; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

81

Tucker M (2009) CST Curation Set: 7132; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

82

Tucker M (2009) CST Curation Set: 7135; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

83

Marin TM, et al. (2008) Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways. Circ Res 103, 813-24
18757826   Curated Info

84

Kim YB, et al. (2008) Cell adhesion-dependent cofilin serine 3 phosphorylation by the integrin-linked kinase.c-Src complex. J Biol Chem 283, 10089-96
18252715   Curated Info

85

Senyo SE, Koshman YE, Russell B (2007) Stimulus interval, rate and direction differentially regulate phosphorylation for mechanotransduction in neonatal cardiac myocytes. FEBS Lett 581, 4241-7
17698065   Curated Info

86

Oh MA, et al. (2007) PKCdelta and cofilin activation affects peripheral actin reorganization and cell-cell contact in cells expressing integrin alpha5 but not its tailless mutant. J Cell Sci 120, 2717-30
17646675   Curated Info

87

Slack-Davis JK, et al. (2007) Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282, 14845-52
17395594   Curated Info

88

Jiang X, Sinnett-Smith J, Rozengurt E (2007) Differential FAK phosphorylation at Ser-910, Ser-843 and Tyr-397 induced by angiotensin II, LPA and EGF in intestinal epithelial cells. Cell Signal 19, 1000-10
17240116   Curated Info

89

Kokkinos MI, Brown HJ, de Iongh RU (2007) Focal adhesion kinase (FAK) expression and activation during lens development. Mol Vis 13, 418-30
17417603   Curated Info

90

van Nimwegen MJ, et al. (2006) Focal adhesion kinase and protein kinase B cooperate to suppress doxorubicin-induced apoptosis of breast tumor cells. Mol Pharmacol 70, 1330-9
16825486   Curated Info

91

Kuramochi Y, Guo X, Sawyer DB (2006) Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 41, 228-35
16769082   Curated Info

92

Rafiq K, et al. (2006) Role of protein-tyrosine phosphatase SHP2 in focal adhesion kinase down-regulation during neutrophil cathepsin G-induced cardiomyocytes anoikis. J Biol Chem 281, 19781-92
16690621   Curated Info

93

Huang D, Khoe M, Ilic D, Bryer-Ash M (2006) Reduced expression of focal adhesion kinase disrupts insulin action in skeletal muscle cells. Endocrinology 147, 3333-43
16574795   Curated Info

94

Swaney JS, et al. (2006) Focal adhesions in (myo)fibroblasts scaffold adenylyl cyclase with phosphorylated caveolin. J Biol Chem 281, 17173-9
16618703   Curated Info

95

Toruner M, et al. (2006) Antianoikis effect of nuclear factor-kappaB through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1. J Biol Chem 281, 8686-96
16407217   Curated Info

96

Menon B, et al. (2006) beta-Adrenergic receptor-stimulated apoptosis in adult cardiac myocytes involves MMP-2-mediated disruption of beta1 integrin signaling and mitochondrial pathway. Am J Physiol Cell Physiol 290, C254-61
16148033   Curated Info

97

Torsoni AS, Marin TM, Velloso LA, Franchini KG (2005) RhoA/ROCK signaling is critical to FAK activation by cyclic stretch in cardiac myocytes. Am J Physiol Heart Circ Physiol 289, H1488-96
15923313   Curated Info

98

van Nimwegen MJ, et al. (2005) Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation. Cancer Res 65, 4698-706
15930288   Curated Info

99

Dallabrida SM, et al. (2005) Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. Circ Res 96, e8-24
15692086   Curated Info

100

Fonseca PM, et al. (2005) Targeting to C-terminal myosin heavy chain may explain mechanotransduction involving focal adhesion kinase in cardiac myocytes. Circ Res 96, 73-81
15576648   Curated Info

101

Lunn JA, Rozengurt E (2004) Hyperosmotic stress induces rapid focal adhesion kinase phosphorylation at tyrosines 397 and 577. Role of Src family kinases and Rho family GTPases. J Biol Chem 279, 45266-78
15302877   Curated Info

102

Boutahar N, Guignandon A, Vico L, Lafage-Proust MH (2004) Mechanical strain on osteoblasts activates autophosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 tyrosine sites involved in ERK activation. J Biol Chem 279, 30588-99
15096502   Curated Info

103

Schliess F, et al. (2004) Involvement of integrins and Src in insulin signaling toward autophagic proteolysis in rat liver. J Biol Chem 279, 21294-301
14985360   Curated Info

104

Berken A, Abel J, Unfried K (2003) beta1-integrin mediates asbestos-induced phosphorylation of AKT and ERK1/2 in a rat pleural mesothelial cell line. Oncogene 22, 8524-8
14627993   Curated Info

105

Heidkamp MC, et al. (2003) Activation of focal adhesion kinase by protein kinase C epsilon in neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol 285, H1684-96
12829427   Curated Info

106

Finnemann SC (2003) Focal adhesion kinase signaling promotes phagocytosis of integrin-bound photoreceptors. EMBO J 22, 4143-54
12912913   Curated Info

107

Sundberg LJ, et al. (2003) An endogenous inhibitor of focal adhesion kinase blocks Rac1/JNK but not Ras/ERK-dependent signaling in vascular smooth muscle cells. J Biol Chem 278, 29783-91
12782622   Curated Info

108

Torsoni AS, et al. (2003) Focal adhesion kinase is activated and mediates the early hypertrophic response to stretch in cardiac myocytes. Circ Res 93, 140-7
12805241   Curated Info

109

Slack-Davis JK, et al. (2003) PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J Cell Biol 162, 281-91
12876277   Curated Info

110

Sawada S, et al. (2003) The tetraspanin CD151 functions as a negative regulator in the adhesion-dependent activation of Ras. J Biol Chem 278, 26323-6
12782641   Curated Info

111

Yi XP, Wang X, Gerdes AM, Li F (2003) Subcellular redistribution of focal adhesion kinase and its related nonkinase in hypertrophic myocardium. Hypertension 41, 1317-23
12732587   Curated Info

112

Pace A, et al. (2003) Phosphospecific site tyrosine phosphorylation of p125FAK and proline-rich kinase 2 is differentially regulated by cholecystokinin receptor type A activation in pancreatic acini. J Biol Chem 278, 19008-16
12651850   Curated Info

113

Yang YC, et al. (2003) Focal adhesion kinase is required, but not sufficient, for the induction of long-term potentiation in dentate gyrus neurons in vivo. J Neurosci 23, 4072-80
12764094   Curated Info

114

Siu MK, Mruk DD, Lee WM, Cheng CY (2003) Adhering junction dynamics in the testis are regulated by an interplay of beta 1-integrin and focal adhesion complex-associated proteins. Endocrinology 144, 2141-63
12697723   Curated Info

115

Messina S, et al. (2003) Specific interactions of neuronal focal adhesion kinase isoforms with Src kinases and amphiphysin. J Neurochem 84, 253-65
12558988   Curated Info

116

Toutant M, et al. (2002) Alternative splicing controls the mechanisms of FAK autophosphorylation. Mol Cell Biol 22, 7731-43
12391143   Curated Info

117

Rice DC, Dobrian AD, Schriver SD, Prewitt RL (2002) Src autophosphorylation is an early event in pressure-mediated signaling pathways in isolated resistance arteries. Hypertension 39, 502-7
11882598   Curated Info

118

Derkinderen P, et al. (2001) Dual role of Fyn in the regulation of FAK+6,7 by cannabinoids in hippocampus. J Biol Chem 276, 38289-96
11468287   Curated Info

119

Hauck CR, Hsia DA, Schlaepfer DD (2000) Focal adhesion kinase facilitates platelet-derived growth factor-BB-stimulated ERK2 activation required for chemotaxis migration of vascular smooth muscle cells. J Biol Chem 275, 41092-9
10998418   Curated Info

120

Müller G, Wied S, Frick W (2000) Cross talk of pp125(FAK) and pp59(Lyn) non-receptor tyrosine kinases to insulin-mimetic signaling in adipocytes. Mol Cell Biol 20, 4708-23
10848597   Curated Info

121

Toutant M, et al. (2000) Autophosphorylation of Tyr397 and its phosphorylation by Src-family kinases are altered in focal-adhesion-kinase neuronal isoforms. Biochem J 348 Pt 1, 119-28
10794722   Curated Info